Oculopharyngeal Muscular Dystrophy

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

PABPN1, LRP12, NUTM2B-AS1, GCG, PABPC1P2, BCL2L2-PABPN1, NRL, PABPC1, SACS, TNNT3, TARDBP, SIRT1, SYNM, SIRT2, OPTN, DNAJB6, GCA, BCL2, TGM2, CTNNB1, PRKAB1, PRKAA2, PRKAA1, PAX7, MLF1, LTBP3, IL6, DNAJA1, HNRNPA2B1, HNRNPA1

Drugs

Trehalose, genetically modified adeno-associated viral vector serotype 9 expressing shRNA as well as a codon-optimised shRNA-insensitive wildtype PABPN1

Interested in hearing about new therapies?

Oculopharyngeal muscular dystrophy (OPMD) is a genetic disorder characterized by slowly progressing muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat. Onset is typically during adulthood, most often between 40 and 60 years of age. Symptoms may include: eyelid drooping (ptosis), arm and leg weakness, and difficulty swallowing (dysphagia). There are two types of OPMD, distinguished by their patterns of inheritance. They are known as the autosomal dominant and autosomal recessive types. Both types are caused by mutations in the PABPN1 gene.Treatment depends on the signs and symptoms present in each individual. Ptosis and dysphagia can be managed with surgery; however, recurrence of symptoms commonly occurs 5-15 years after intervention.